S. Klaesson

发表

DOES HIGH‐DOSE INTRAVENOUS IMMUNE GLOBULIN TREATMENT AFTER BONE MARROW TRANSPLANTATION INCREASE MORTALITY IN VENO‐OCCLUSIVE DISEASE OF THE LIVER?

P. Ljungman, J. Winiarski, J. Aschan, 1995, Transplantation.

Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies.

P. Ljungman, M. Remberger, O. Ringdén, 1998, Transplantation.

N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation

S. Lehmann, M. Remberger, O. Ringdén, 2000, Bone Marrow Transplantation.

rhEPO in hematopoietic stem cell mobilization, transplantation and in-vitro expansion

S. Klaesson, 2002 .

Clinical use of rHuEPO in bone marrow transplantation

S. Klaesson, 1999, Medical oncology.

Cytomegalovirus viraemia and specific T‐helper cell responses as predictors of disease after allogeneic marrow transplantation

G. Gahrton, P. Ljungman, O. Ringdén, 1993, British journal of haematology.

Long‐term persistence of oligoclonal serum IgM repertoires in patients treated with allogeneic bone marrow transplantation (BMT)

I. Lundkvist, M. Remberger, O. Ringdén, 2000, Clinical and experimental immunology.

Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.

P. Ljungman, O. Ringdén, B. Lönnqvist, 1996, Bone marrow transplantation.

Immune Modulatory Effects of Immunoglobulins on Cell‐Mediated Immune Responses In Vitro

I. Lundkvist, M. Remberger, O. Ringdén, 1993, Scandinavian journal of immunology.

Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation.

P. Ljungman, M. Remberger, O. Ringdén, 1998, Blood.

Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin.

P. Ljungman, O. Ringdén, B. Lönnqvist, 1994, Bone marrow transplantation.

Treatment with erythropoietin after allogeneic bone marrow transplantation: a randomized, double-blind study.

P. Ljungman, O. Ringdén, B. Lönnqvist, 1994, Transplantation Proceedings.

An ethnic role for chronic, but not acute, graft‐versus‐host disease after HLA‐identical sibling stem cell transplantation

P. Ljungman, M. Remberger, O. Ringdén, 2001, Transplantation proceedings.

An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation.

P. Ljungman, M. Remberger, O. Ringdén, 2001, European journal of haematology.

Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis

P. Ljungman, M. Remberger, O. Ringdén, 1998, Bone Marrow Transplantation.

Norethisterone Treatment, a Major Risk-Factor for Veno-Occlusive Disease in the Liver After Allogeneic Bone Marrow Transplantation

P. Ljungman, M. Remberger, O. Ringdén, 1998 .

Increased risk of relapse in patients with chronic myelogenous leukemia given T‐cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft‐versus‐host disease

P. Ljungman, O. Ringdén, B. Sundberg, 1993, European journal of haematology.

Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings.

P. Ljungman, O. Ringdén, B. Sundberg, 1992, Bone marrow transplantation.

Improved survival after bone marrow transplantation for early leukemia using busulfan–cyclophosphamide and individualized prophylaxis against graft‐versus‐host disease: a long‐term follow‐up

M. Remberger, J. Aschan, J. Mattsson, 1999, Clinical transplantation.